• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Partnership takes IOP monitoring system to Latin America

Article

A new partnership between Addition Technology Inc. and Switzerland-based Sensimed AG will have the former company rolling out the latter company?s IOP monitoring system (Sensimed Triggerfish) in Latin America.

Des Plaines, IL-A new partnership between Addition Technology Inc. and Switzerland-based Sensimed AG will have the former company rolling out the latter company’s IOP monitoring system (Sensimed Triggerfish) in Latin America.

The contact lens continuously monitors IOP fluctuations to facilitate the management of related diseases such as glaucoma. By providing a 24-hour profile of IOP, the technology is designed to help ophthalmologists better understand the condition of the patient, provide personalized treatment, and monitor the efficacy of the treatment over time.

Addition Technology will handle the registration process and the commercialization of the product in Latin America, where a high incidence of glaucoma exists. The company already is broadly present across the continent, maintaining close relationships with key opinion leaders and ophthalmologists, according to its management.

“Their presence and experience in Latin America will open a new market for our company and will enable a large population suffering from glaucoma to have access to our technology,” said Jean-Marc Wismer, chief executive officer (CEO) of Sensimed.

William Flynn, president and CEO of Addition Technology, said, “We are very excited about our relationship with Sensimed and the opportunity to bring this valuable technology to glaucoma specialists in Latin America. I believe this system will completely change the way glaucoma [is] managed in the future.”

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.